Stock Screener App

無料 -

インストール

1.9688

4.62% -0.0188

Veraxa Biotech Ag (VRXA)

概要ニュース株価時系列ディスカッション予測

Veraxa Biotech Ag (VRXA) 最新ニュース

VERAXA Biotech AG: Valuation Ratios, Analysts' Forecasts - marketscreener.com

Veraxa Biotech (VRXA) interim CFO discloses zero share ownership - Stock Titan

VERAXA Biotech Leverages AI to Advance Precision Oncology Pipeline - citybuzz -

VERAXA Biotech Leverages AI to Enhance Precision Oncology Pipeline - citybuzz -

Dividend HistoryVeraxa Biotech AG (VRXA) - Zacks Investment Research

VRXA: Veraxa Biotech AGInsider Transations - Zacks Investment Research

VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - USA Today

AQR group (VRXA) discloses 658,138-share Veraxa Biotech position under 5% threshold - Stock Titan

Veraxa Biotech AG Ord Shs (VRXA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Veraxa Biotech Holding AG SEC Filing (Aug 10, 2026) - Stock Titan

VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer - USA Today

VERAXA Biotech Advances Antibody Therapeutics with Innovative BiTAC Platform - citybuzz -

Veraxa Biotech Holding AG SEC Filing (Aug 7, 2026) - Stock Titan

VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-G - Benzinga

VERAXA Biotech Advances VXA-222 Cancer Program and Expands Patent Portfolio - citybuzz.co

VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform - USA Today

Veraxa Biotech (VRXA) grows patent estate for BiTAC cancer platforms - Stock Titan

Veraxa Biotech files first BiTAC patent applications in 2026 By Investing.com - Investing.com Canada

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates - The Manila Times

VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures - Benzinga

Veraxa Biotech AG Ord Shs (VRXA) Institutional Confidence - TradingKey

Veraxa Biotech AG Ord Shs (VRXA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Veraxa Biotech AG Ord Shs (VRXA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Veraxa Biotech (VRXA) moves bispecific ADC VXA-222 program forward - Stock Titan

VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - NewMediaWire

Veraxa advances cancer therapy program with OmniAb By Investing.com - Investing.com South Africa

Veraxa Biotech AG Ord Shs (VRXA) Cash Flow - TradingKey

Veraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone - BioPharm International

VERAXA Biotech Advances Bispecific ADC Program VXA-222 Under OmniAb Collaboration - citybuzz -

VERAXA Biotech Shareholders Overwhelmingly Approve Corporate Governance and Financing Measures - citybuzz -

Veraxa Biotech AG Ord Shs (VRXA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Veraxa Biotech advances bispecific ADC from Omniab collaboration - BioWorld News

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - The Manila Times

VERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb - Quiver Quantitative

VERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens - Stock Titan

Veraxa Biotech AG Ord Shs (VRXA) Balance Sheet - TradingKey

Veraxa Biotech AG Ord Shs (VRXA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Veraxa Biotech AG Ord Shs (VRXA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Veraxa Biotech AG Ord Shs (VRXA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

VRXA|Veraxa Biotech AG Ord Shs|Price:1.800|Chg%:-0.060 - TradingKey

Veraxa Biotech AG Ord Shs (VRXA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Veraxa Biotech AG Ord Shs (VRXA) Income Statement - TradingKey

Veraxa Biotech shareholders approve governance changes By Investing.com - Investing.com India

VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth - The Manila Times

VERAXA Biotech AG (VRXA) Appoints Christoph Erkel as Chief Scientific Officer - NewMediaWire

Veraxa Biotech AG Revenue Breakdown – FWB:J8L0 - TradingView

VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel As Chief Scientific Officer - Menafn

VERAXA Biotech (VRXA) Advances BiTAC(R)-TCE Development With Positive Regulatory Feedback From Germany - Yahoo Finance

VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Lead BiTAC Platform Development - citybuzz -

VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio - The Manila Times

Veraxa Biotech names Christoph Erkel as chief scientific officer By Investing.com - Investing.com UK

VERAXA Biotech AG Appoints Christoph Erkel, Ph.D., as Chief Scientific Officer - Quiver Quantitative

VERAXA Taps 20-Year Antibody Expert to Guide New Cancer Treatments - Stock Titan

VERAXA Biotech Receives Positive Regulatory Guidance for BiTAC-TCE Platform from German Authority - citybuzz -

VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program - USA Today

Oliver Rolf Baumann Net Worth (2026) - GuruFocus

INSM

$124.14

1.25%

RPRX

$61.04

0.44%

BNTX

$113.17

2.89%

ALNY

$232.38

1.64%

ONC

$371.86

0.68%

RVMD

$210.77

0.61%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | エドガーでオープン | ロイターで開く